PRINCETON BIOMEDITECH CORP

Princeton Biomeditech Corp specializes in the design, development, and manufacturing of in-vitro diagnostic substances and analytical laboratory instruments for rapid infectious disease detection. The company’s technical expertise centers on point-of-care diagnostic platforms, including multiplex antigen assays for simultaneous detection of SARS-CoV-2, influenza A, and influenza B, integrated with proprietary reader systems. Their work involves precision formulation of reagents, microfluidic device integration, and validation of clinical-grade diagnostic kits compliant with FDA and CDC guidelines for over-the-counter use. Key differentiators include rapid turnaround in product development cycles and the ability to scale manufacturing of complex diagnostic kits under stringent quality control standards for public health emergencies. The contractor maintains a focused relationship with the Department of Health and Human Services, delivering critical diagnostic solutions during national health crises. Their engagements center on high-priority public health initiatives requiring rapid deployment of reliable, field-deployable testing technologies, indicating a trusted partnership in emergency response and preparedness programs. Princeton Biomeditech Corp operates primarily within NAICS 325413 (in-vitro diagnostic substance manufacturing) and 334516 (analytical laboratory instrument manufacturing), positioning itself at the intersection of molecular diagnostics and medical device engineering. The company specializes in the commercialization of rapid diagnostic systems for infectious disease surveillance, serving the public health and clinical diagnostics markets with FDA-cleared and emergency use authorized products. As a small business structured as a 2L entity based in Monmouth Junction, New Jersey, Princeton Biomeditech Corp maintains a targeted geographic footprint with deep alignment to federal health security priorities. While currently holding no formal government certifications, its demonstrated ability to deliver complex diagnostic systems under tight timelines underscores its niche role in the U.S. biomedical response ecosystem.